YARW Yarrow Bioscience, Inc.
Listings ·
Nasdaq granted VYNE an extra 180 calendar days, until September 7, 2026, to meet the $1.00 minimum bid price. Its 2025 net loss was $26,483 thousand, and the company says its cash is enough only through the closing of its planned merger with Yarrow Biosciences.
Nasdaq told the company on September 11, 2025 that its stock closed below $1.00 for 30 consecutive business days. It has until March 10, 2026 to regain compliance, and the Nasdaq Capital Market listing is unchanged for now.
VYNE Therapeutics, now Yarrow Bioscience, has until March 10, 2026 to lift its closing bid price back to at least $1.00 per share.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $19.2 million | $30.9 million |
| Net income (loss) | -$26.5 million | -$39.8 million |
| Cash from operations | -$33.1 million | -$34.0 million |
| Cash and equivalents | $24.0 million | $19.9 million |
| Short-term investments | $5.0 million | $41.6 million |
Our latest story on this, dated Sep 12, 2025: "VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq notice for sub-$1.00 stock". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 11, 2026: "VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq bid price extension to Sept. 7, 2026". The story links the filing or release it is based on. Read the story.
Yarrow Bioscience, Inc. trades under the ticker YARW on NASDAQ.
Yarrow Bioscience, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Yarrow Bioscience, Inc. is 1566044. Its filings are on SEC EDGAR.
2,669,746 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Yarrow Bioscience, Inc. under United States.
Our directory classifies Yarrow Bioscience, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Yarrow Bioscience, Inc. is US92941V4077.
aibio.space lists Yarrow Bioscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Yarrow Bioscience, Inc. reported a net loss of $26.5 million for the fiscal year ended Dec 31, 2025, and used $33.1 million of cash in operations, per its annual report to the SEC.
$19.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$22.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Yarrow Bioscience, dated Mar 11, 2026: "VYNE Therapeutics (now Yarrow Bioscience) gets Nasdaq bid price extension to Sept. 7, 2026". Nasdaq granted VYNE an extra 180 calendar days, until September 7, 2026, to meet the $1.00 minimum bid price. Its 2025 net loss was $26,483 thousand, and the company says its cash is enough only through the closing of its planned merger with Yarrow Biosciences. Source.
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a reverse stock split. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio